Transcriptome analysis suggests a role for the differential expression of cerebral aquaporins and the MAPK signalling pathway in human temporal lobe epilepsy by Salman, Mootaz M. et al.
1 
 
Transcriptome analysis suggests a role for the differential expression of cerebral 1 
aquaporins and the MAPK signalling pathway in human temporal lobe epilepsy 2 
Mootaz M. Salman1, Mariam A. Sheilabi1, Dev Bhattacharyya2, Philip Kitchen3, Alex C. 3 
Conner3, Roslyn M. Bill4, M. Nicola Woodroofe1, Matthew T. Conner1,5* and Alessandra P. 4 
Princivalle1* 5 
1Biomolecular Sciences Research Centre (BMRC), Sheffield Hallam University, Howard 6 
Street, Sheffield, S1 1WB.  7 
2Neurosurgery Department, Royal Hallamshire Hospital, Sheffield, UK.  8 
3School of Clinical and Experimental Medicine, University of Birmingham, Edgbaston, 9 
Birmingham B15 2TT, UK. 10 
4School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, 11 
UK.  12 
5School of Biology, Chemistry and Forensic Science, University of Wolverhampton, Wulfruna 13 
St, Wolverhampton WV1 1LY 14 
 15 
*Corresponding Authors: 16 
A.P. Princivalle 17 
1Biomolecular Research Centre (BMRC),  18 
Sheffield Hallam University,  19 
Howard Street, Sheffield, S1 1WB. 20 
Email: a.p.princivalle@shu.ac.uk 21 
M T Conner 22 
5School of Biology Chemistry and Forensic Science,  23 
University of Wolverhampton,  24 
Wulfruna St, 25 
Wolverhampton WV1 1LY 26 
Email: m.conner@wlv.ac.uk  27 
 28 
2 
 
 29 
 30 
Running title: The role of AQPs and MAPK in TLE pathogenesis. 31 
The total number of pages 40, figures 6, tables 2. Supplementary 1 figure and 1 table.  32 
The total number of words in: (9801) the whole manuscript; (250) the Abstract. 33 
Keywords: Aquaporin, AQP4, TLE, Epilepsy, AQP1, Microarray. 34 
 35 
Abstract 36 
Epilepsies are common disorders of the central nervous system (CNS), affecting up to 2% of 37 
the global population. Pharmaco-resistance is a major clinical challenge affecting about 30% 38 
of temporal lobe epilepsy (TLE) patients. Water homeostasis has been shown to be crucial 39 
for regulation of neuronal excitability. The control of water movement is achieved through a 40 
family of small integral membrane channel proteins called aquaporins (AQPs). Despite the 41 
fact that changes in water homeostasis occur in sclerotic hippocampi of people with TLE, the 42 
expression of AQPs in the epileptic brain is not fully characterised. This study uses 43 
microarray and ELISA methods to analyse the mRNA and protein expression of the human 44 
cerebral AQPs in sclerotic hippocampi (TLE-HS) and adjacent neocortex tissue (TLE-NC) of 45 
ten TLE patients. 46 
The expression of AQP1 and AQP4 transcripts was significantly increased, while that of the 47 
AQP9 transcript was significantly reduced in sclerotic hippocampi compared to TLE-NC. 48 
AQP4 protein expression was also increased while expression of AQP1 protein remained 49 
unchanged, and AQP9 was undetected. 50 
Microarray data analysis identified 3,333 differentially regulated genes and suggested the 51 
involvement of the MAPK signalling pathway in TLE pathogenesis. Proteome array data 52 
validated the translational profile for 26 genes within the MAPK pathway that were identified 53 
as differentially expressed from microarray analysis. ELISA data showed that p38 and JNK 54 
inhibitors decrease AQP4 protein levels in cultured human primary cortical astrocytes. 55 
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Elucidating the mechanism of selective regulation of different AQPs and associated 56 
regulatory proteins may provide a new therapeutic approach to epilepsy treatment.  57 
 58 
 59 
 60 
 61 
 62 
 63 
Introduction 64 
Epilepsies are among the most common disorders of the central nervous system (CNS). It is 65 
estimated that over 65 million people worldwide suffer from these debilitating conditions 66 
(Ngugi et al., 2010; Moshé et al., 2015). Temporal lobe epilepsy (TLE) accounts for about 67 
one-third of all patients with epilepsy (Heuser et al., 2012). The majority of current anti-68 
epileptic drugs (AEDs) target the ion channels that mediate neuronal excitability (Rogawski 69 
& Löscher, 2004; Landmark, 2006), however about 30% of patients become medically 70 
refractory to AEDs (Löscher, 2011; Löscher et al., 2013). Pharmaco-resistance in TLE is 71 
often associated with hippocampal sclerosis (HS). The sclerotic hippocampus is 72 
characterized by neuronal loss, astrogliosis and increased microvascular density (Blümcke 73 
et al., 2012; Alonso-Nanclares & DeFelipe, 2014), particularly at the perivascular end-feet of 74 
astrocytes (Eid et al., 2005). 75 
 76 
Astrocytes play a major role in regulating water and ion (particularly K+) homeostasis in the 77 
brain. The association of K+ homeostasis and water transport is known to mediate synaptic 78 
transmission by modulating the extracellular environment around neurons (Simard & 79 
Nedergaard, 2004); additionally astrocytes can be depolarized and produce an action 80 
potential exhibiting neuronal-like characteristics (Bordey & Sontheimer, 1998). Water 81 
homeostasis is an important factor in modulating seizure susceptibility (Andrew, 1991; 82 
Schwartzkroin et al., 1998; Lee et al., 2012). Magnetic resonance imaging (MRI) of sclerotic 83 
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hippocampi from TLE sufferers (TLE-HS) showed an increase in T2-weighted signal (Bronen 84 
et al., 1991; Dawe et al., 2014) and diffusion-weighted imaging demonstrated higher 85 
diffusion coefficient in TLE-HS patients compared to controls (Wieshmann et al., 1999). All 86 
these data indicated higher free water content in sclerotic hippocampi tissue (Lee et al., 87 
2004; Heuser et al., 2010). 88 
 89 
The control of water movement into and out of cells is achieved via a family of small integral 90 
membrane proteins called aquaporins (AQPs). Thirteen human AQPs (AQP 0-12), have 91 
been identified and characterised (Day et al., 2014). AQP4 is the predominant AQP in the 92 
CNS and it has been identified and characterised in both neurons (Binder et al., 2006) and 93 
glia (Nielsen et al., 1997). In the human hippocampus, AQP4 has been found in the Cornu 94 
Ammonis (CA) and dentate gyrus (DG) areas. At the cellular and subcellular level, AQP4 is 95 
abundantly expressed in the plasma membrane of the astrocytes that sheathe the 96 
glutamatergic synapses, and shows the highest expression in perivascular astrocytes, where 97 
it is localised to the plasma membrane of astrocytic end-feet at the glia limitans (Lee et al., 98 
2004; Gleiser et al., 2016). AQP4 is co-localized with inwardly-rectifying K+ channels (Kir4.1) 99 
and glial K+ uptake is attenuated in AQP4 knockout mice compared to wild-type, indicating a 100 
functional interaction (Padmawar et al., 2005; Binder et al., 2006; Binder et al., 2012). In the 101 
sclerotic hippocampus, astrocytes have fewer Kir4.1 channels and immunohistological 102 
studies have indicated that Kir4.1 is lost from perivascular end-feet in sclerotic hippocampi of 103 
TLE patients (Heuser et al., 2012). It is not known if this change in expression is due to; or 104 
driven by, changes at the transcript level or changes in protein stability/degradation. There is 105 
also some controversy in the literature concerning the exact nature of the relationship 106 
between AQP4 and Kir4.1 in astrocytes, with one study suggesting that glial AQP4 and 107 
Kir4.1 do not interact functionally (Zhang & Verkman, 2008). 108 
Other AQPs have been identified in the CNS: AQP1 in the dorsal-root ganglia (Shields et al. 109 
2007) and in the epithelium of the choroid plexus, where cerebrospinal fluid (CSF) is 110 
produced (Oshio et al., 2005) and AQP9 in the substantia nigra (Badaut et al., 2004). AQP1, 111 
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3, 4, 5, 8, 9 and 11 have been shown to be expressed at gene and protein levels in the 112 
rodent brain, principally in astrocytes (Gorelick et al., 2006; Yang et al., 2009; Badaut et al., 113 
2014). Moreover, AQPs 3, 5 and 8 are expressed in the DG area in both astrocytes and 114 
neurons (Yang et al., 2009). However, there is still little known about the expression profile 115 
of human cerebral AQPs, particularly in TLE patients. For example, there is contradictory 116 
evidence describing the expression of AQPs in sclerotic and non-sclerotic hippocampi: Lee 117 
et al showed AQP1 and AQP4 protein expression in astrocytes located in the hippocampal 118 
tissues, but only AQP4 protein expression was found to be upregulated in perivascular 119 
astrocytes in the sclerotic hippocampi tissue of TLE patients (n=4) compared to non-sclerotic 120 
hippocampi (n=5). Eid et al. reported an increase in AQP4 protein in mesial temporal lobe 121 
epilepsy (MTLE) patient (n=6) hippocampi compared to non-MTLE controls (n=6), however a 122 
simultaneous loss of perivascular AQP4 localization was seen and attributed to loss of 123 
dystrophin localization. Bebek et al. reported that there was no difference in the expression 124 
of AQP1 and AQP4 transcripts nor the AQP4 protein in 23 patients. Jamali et al. showed an 125 
increase in AQP1 transcript following a microarray study on hippocampal tissues from 15 126 
TLE patients; however, their findings were not consistent following RT-PCR validation and 127 
therefore the gene was discounted from further analysis. 128 
 129 
A number of studies have investigated the possible mechanisms involved in AQP regulation; 130 
these studies identified the p38 Mitogen-activated Protein Kinase-dependent (MAPK) 131 
pathway as the possible primary mechanism controlling the altered expression of some 132 
AQPs (Fujita et al., 2003; Yang et al., 2013b). The MAPK family consists of three major 133 
pathways, the extracellular signal regulated kinase (ERK) pathway, the p38 pathway and C-134 
Jun N-terminal kinases (JNK) pathway. The MAPK pathway has been implicated in 135 
increased epileptic seizures due to hippocampal sclerosis (Pernice et al., 2016). The 136 
purpose of this current study was to analyse gene expression and protein profiling in TLE-137 
HS and the non-sclerotic temporal lobe that had no ictal or inter-ictal activity (TLE-NC; 138 
neocortex). Gene network analysis using Database for Annotation, Visualization, and 139 
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Integrated Discovery (DAVID) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) 140 
analysis identified the MAPK pathway as the most likely pathway affected in TLE identified in 141 
the microarray. ELISA was conducted to investigate the involvement of p38, EK1/2 and JNK 142 
MAPKs in regulating AQP4 protein expression in primary human astrocytes using the 143 
specific inhibitors: SB203580, PD98059 and SP600125, respectively. Direct targeting of 144 
AQPs and/or the molecular mechanisms of their regulation via the MAPK signalling 145 
pathways could open new horizons for more specific and targeted treatments for TLE. 146 
 147 
Materials and methods: 148 
Sample collection and patients' clinical information:  149 
This research was approved by South Yorkshire research ethics committee (08/H1310/49) 150 
and it followed the code of ethics of the World Medical Association (2001). The samples 151 
were obtained from the Royal Hallamshire Hospital (R&D approval STH15210). All samples 152 
were obtained with the understanding and the written consent of each patient. The sample 153 
collection procedure fully conformed to the Code of Ethics of the World Medical Association 154 
(Declaration of Helsinki), British Medical Journal (1964). 155 
Patients with pharmaco-resistant TLE associated with unilateral hippocampal sclerosis were 156 
recruited. The diagnosis of TLE-HS was made by the treating clinician based on MRI brain 157 
scan and inter-ictal and ictal EEG characteristics, being consistent with a seizure focus in the 158 
hippocampus within the temporal lobe. The total number of patients used for this study were 159 
ten TLE patients (6 females and 4 males), their age at surgery was 38.2 ± 10.2 years, the 160 
average age at onset of first non-febrile seizure was 11.6 ± 9.9 years and the average 161 
duration of epilepsy was 26.6 ± 15.8 years. These patients underwent a therapeutic selective 162 
amygdalohippocampectomy. After surgery, two samples were obtained: sclerotic 163 
hippocampus (TLE-HS), and non-spiking neocortex (TLE-NC). Full clinical information for 164 
the patients is shown in Table 1. 165 
 166 
Microarray analysis (MA) 167 
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Total RNA was extracted using SV Total RNA Isolation System (Promega, Z3100) according 168 
to the manufacturer's instructions. The quality and purity of the prepared RNA was assayed 169 
using a NanoDrop-1000 spectrophotometer and Agilent Bioanalyser-2100, to ensure only 170 
high-quality RNA samples with A260/A280 ratio of 1.8 to 2.0 and an A260/A230 ratio of > 2.0 were 171 
used for the microarray study. Starting from 100 ng of RNA, cRNA samples were 172 
synthesized and labelled with Cy3 or Cy5 using the Two-colour Low Input Quick Amp 173 
labelling kit (Agilent Technologies, 5190-2306). TLE-HS hippocampi were labelled with Cy5 174 
and TLE-NC samples were labelled with Cy3.  Equal amounts of the labelled TLE-HS and 175 
TLE-NC samples were co-hybridized onto SurePrint G3 Human Gene Expression 8x60K 176 
Microarrays (Agilent Technologies, G4851A). The microarray array was scanned on Agilent 177 
Technologies SureScan scanner. Raw data was extracted using Agilent feature extraction 178 
software (version 10.7.1) and was then normalized by the locally weighted scatter plot 179 
smoothing (LOWESS) normalization method. The Rank Product (RP) test was used to 180 
identify the differentially expressed genes (P < 0.05) using Multi-Experiment Viewer (MeV) 181 
software, version 4.9 (Saeed et al., 2003; Breitling et al., 2004; Koziol, 2010). The list of up- 182 
and down-regulated genes was submitted to the bioinformatics and functional annotation 183 
tool provided by DAVID, version 6.7 (Huang et al., 2009a; b). Then KEGG pathway 184 
enrichment analysis was done to identify potential pathways that are possibly associated 185 
with TLE-HS pathophysiology (http://david.abcc.ncifcrf.gov/). 186 
In order to obtain biological information underpinning the molecular mechanisms and 187 
regulatory networks associated with TLE pathogenesis, microarray data was further 188 
assessed using the “TargetMine” (http://targetmine.mizuguchilab.org/) and the Gene 189 
Ontology Consortium (http://geneontology.org/) bioinformatics tools to obtain functional 190 
annotation clustering and gene ontology (GO) terms for the differentially-regulated genes 191 
(DEGs). Key results are summarised along with gene count, p value and fold enrichment  in 192 
supplementary Table 1. 193 
Sandwich enzyme-linked immunosorbent assay (ELISA) 194 
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A 96-well microtiter flat-bottomed polystyrene plate (Nunc, Wiesbaden, Germany) was 195 
coated by overnight incubation at 4°C with 5 µl/well of either rabbit polyclonal anti-196 
AQP4 (Abcam, ab46182) diluted 1:500, rabbit polyclonal anti-AQP1 (Santa Cruz, sc-208110) 197 
diluted 1:400 or rabbit polyclonal anti-AQP9 (LS-C20770) diluted 1:500; all antibodies were 198 
diluted in carbonate/bicarbonate buffer (pH 9.6). The plates were washed twice for 5 minutes 199 
with Phosphate Buffered Saline and 0.05% Tween 20 (PBS-T) (pH 7.5). The remaining 200 
unsaturated protein-binding sites in the coated wells were blocked by adding blocking buffer 201 
(5% non-fat dry milk/PBS) and then incubated overnight at 4°C with gentle shaking. Plates 202 
were washed twice for 5 minutes with PBS-T. Hippocampal proteins were extracted using 203 
CelLyticTM (Sigma, Cat. No. C2978) supplemented with protease inhibitor cocktail (Sigma, 204 
Cat. No. P2714, 1:100). The total protein concentration was determined using Pierce™ BCA 205 
Protein Assay Kit (Thermofisher Scientific, Cat. No. 23225) following the manufacturer’s 206 
procedure. 100 μl equally diluted samples at a concentration of 600 µg/ml were added to 207 
each well and incubated for 90-120 minutes at 37°C. Samples were then aspirated and the 208 
plates were washed twice with PBS-T. 100 μl of either the 1:1 diluted mouse monoclonal 209 
anti-AQP4 antibody (Abcam, ab9512), mouse monoclonal anti-AQP1 (Abcam, ab11025), or 210 
goat polyclonal anti-AQP9 (Santa Cruz F-17; sc-14988) were added to each well. The plates 211 
were covered with adhesive plastic and incubated for 2 h at 37°C and then washed twice for 212 
5 minutes with PBS-T. Then 100 μl of horseradish peroxidase (HRP)-conjugated secondary 213 
antibody, either chicken anti-mouse (Santa Cruz, sc-2954) for AQP4 and AQP1 or chicken 214 
anti-goat (c-2953) for AQP9, diluted at 1: 5,000 in freshly-prepared blocking buffer, was 215 
added to each well and incubated for 30 minutes at 37°C. The plates were washed (with 216 
gentle shaking) four times for 5 minutes with 200 µl PBS-T, followed by a single wash with 217 
PBS. The plates were incubated with 100 μl/well of RayBioTM TMB One-Step Substrate 218 
Reagent, (Raybiotech; Cat. No. J120215098) under light-protected conditions, at room 219 
temperature for 30 minutes. After the colour was developed, the reaction was stopped by 220 
adding 50 μl of 2 M H2SO4. The absorbance values were then immediately measured at 450 221 
nm using a Perkin Elmer Wallac 1420 Victor2 microplate reader. 222 
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Proteome Profiling 223 
Proteome Profiler™ Human MAPK array (R&D Systems, ARY002B) was used to investigate 224 
the possible role of signaling molecules of all three major families of MAPKs, the 225 
extracellular signal-regulated kinases (ERK1/2), c-Jun N-terminal kinases (JNK1-3), and 226 
different p38 isoforms (α/β/δ/γ) in TLE-HS. Protein from 3 matching pairs of TLE-HS and 227 
TLE-NC patient samples were extracted using CelLyticTM 10ml per gram of tissue (Sigma, 228 
C2978) supplemented with protease inhibitor cocktail 1:100 (Sigma, P2714). The total 229 
protein was quantified using Pierce™ BCA protein assay kit (Thermofisher scientific, 23225) 230 
following the manufacturer's procedure. Each proteome profiler membrane was then 231 
incubated with 300 μg of protein lysate, according to the manufacturer's instructions. The 232 
HRP-conjugated streptavidin provided in the kit was replaced with IRDye® 800CW 233 
Streptavidin (LI-COR, 926-32230) and it was diluted at 1:2000 using the array buffer 5 (R&D 234 
Systems, ARY002B). All of the following steps were performed according to the 235 
manufacturer’s recommendation. The arrays were scanned with LI-COR Odyssey® Infrared 236 
Imaging System and quantified with Image Studio™ software (LI-COR) to determine the 237 
relative amount of the specific MAPK proteins.  238 
Cell Culture 239 
Primary human cortical astrocytes (Sciencell, Cat. No. 1800) were plated into 75 cm2 culture 240 
flasks (Thermo Scientific Nunc Cell Culture Treated EasyFlasks) and cultured routinely in 241 
Astrocyte Medium (Sciencell; 1801) containing 1% fetal bovine serum (FBS, Sciencell Cat. 242 
No. 0010), 5 ml astrocyte growth supplement (AGS, Sciencell Cat. No. 1852) and 5 ml 1% 243 
penicillin/streptomycin solution (P/S, Sciencell Cat. No. 0503). Cultures were maintained at 244 
37°C and 5% air in a humidified environment.  245 
Treatment with p38, ERK1/2 and JNK inhibitors 246 
In order to investigate the possible role of p38, ERK1/2 and JNK in the differential regulation 247 
of AQP4 expression in astrocytes, the effects of the p38 inhibitor SB203580 at 10 µM  (Hua 248 
et al., 2002), ERK1/2 inhibitor PD98059 at 10 µM (Hua et al., 2002) and the JNK inhibitor 249 
SP600125 at 40 µM (Wallace et al., 2012) were examined in human primary cortical 250 
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astrocytes for 6h. Data are presented as a fold-change normalised to the experimental 251 
control (n=4). In all cases, cells were at least 92% viable. 252 
Statistical analysis   253 
Microarray analysis, ELISA and proteome profiling data were found not to be normally 254 
distributed using a Shapiro-Wilk test, therefore Kruskal-Wallis with Conover– Inman post hoc 255 
analysis tests were used to identify significant differences between samples (P ≤ 0.05 was 256 
taken as significant).  257 
 258 
Results 259 
Microarray (MA) gene expression analysis 260 
In the MA analysis on the SurePrint G3 human gene expression 60K microarrays (Agilent 261 
Technologies, G4851A), a total number of 34,197 uniquely-annotated probes were present 262 
and significant differences in the expression levels of 3,333 genes were identified. In the 263 
TLE-HS tissue, 1,821 genes (5% of all detected genes) were significantly up regulated and 264 
1,511 genes (4%) were significantly down regulated compared to TLE-NC tissue from seven 265 
patients. Figure 1 shows the data for all investigated cerebral AQPs and their associated 266 
Kir4.1 channel. Fold change (FC) was calculated by dividing the value representing the gene 267 
expression in TLE-HS by the corresponding TLE-NC value. AQP1 and AQP4 mRNA levels 268 
were both significantly increased (4.03-fold ± 0.89-, p<0.0001 (n= 7) and 3.42-fold ±0.58, 269 
p<0.0001 (n= 7); respectively). AQP9 mRNA levels were significantly reduced to 0.31-fold 270 
±0.06, p=0.01 (n= 7). There was no significant difference in mRNA levels for AQP3, AQP5, 271 
AQP8, AQP11 or Kir4.1.  272 
Protein expression levels of AQP4 and AQP1  273 
The AQP ELISA data demonstrated a significant increase in AQP4 protein expression in 274 
TLE-HS samples (2.53-fold ± 0.1-fold, p<0.0001 n= 3) compared to TLE-NC samples from 275 
the same set of patients (Figure 2A). AQP1 protein was measurable in both samples, 276 
however there was no detectable significant difference (p=0.065) in AQP1 protein levels in 277 
the sclerotic TLE-HS samples compared to non-sclerotic TLE-NC samples (Figure 2B). The 278 
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expression of AQP9 protein could not be detected using our custom-made ELISA system 279 
with the combination of antibodies used. 280 
DAVID/KEGG pathway analysis of MA data  281 
The 3,333 differently-regulated genes from the MA analysis were submitted to the 282 
bioinformatics database, DAVID, using KEGG database for pathway enrichment analysis. To 283 
minimize false positives among significantly-enriched functions, a false discovery rate (FDR) 284 
≤0.05 (-log P-value = 1.33) was used to determine the probability that each biological 285 
function assigned to that data set was due to chance alone. The calcium signalling pathway, 286 
MAPK signalling pathway and neuroactive ligand-receptor interaction pathway showed the 287 
highest enrichment scores in the sclerotic TLE-HS tissue compared to TLE-NC (Figure 3). 288 
The MAPK signalling pathway was the second most highly-represented pathway with an 289 
enrichment score of 6.1 (after the Ca2+ signalling pathway with an enrichment score of 8.7) 290 
and the one with the highest number of significantly-regulated genes. The expression of 50 291 
MAPK genes was altered: 27 genes had a higher expression and 23 genes had a lower 292 
expression in TLE-HS compared to the TLE-NC tissue. Their distribution profile within the 293 
MAPK pathway is illustrated in Figure 4. 294 
MAPK signalling profile in TLE-NC and TLE-HS samples 295 
Since analysis of the MA data demonstrated the involvement of the MAPK signalling 296 
pathway in TLE pathophysiology (Figures 3 and 4), 26 of the significantly-enriched MAPK 297 
related genes (Figure 5a) were investigated at the protein level using a Proteome Profiler 298 
Human MAPK Array Kit (Figure 5b). Transcription levels were determined by reanalysing the 299 
MA data for each of these 26 individual genes to determine the protein expression level in 300 
TLE compared to TLE-NC. In addition, the transcriptional and translational expression FC of 301 
a number of significant MAPKs was calculated by dividing the gene or protein expression 302 
level in TLE-HS by its corresponding TLE-NC value as shown in Table 2.  303 
 304 
The results show significant up-regulation of ERK2 and MMK3 at both the gene (2.75-fold 305 
±0.02; p<0.0001; 1.15-fold ±0.09; p<0.0001) and protein level (2.33-fold ±0.65; p=0.02; 2.26-306 
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fold ±0.53; p=0.02). There were also significant increases in protein levels of AKT Pan (3.78-307 
fold ±0.48; p=0.0213); p53 (2.89-fold ±0.47; p=0.021) and RSK2 (1.75-fold ±0.28; p=0.02) 308 
although there were no significant differences at the mRNA level.  Several genes showed 309 
significant expression changes that were not accompanied by a corresponding change in 310 
protein expression. These included the up-regulation of ERK1 (1.34-fold ±0.02; p<0.0001), 311 
GSK3-beta (1.81-fold ±0.01; p<0.0001), HSP27 (2.01-fold ±0.27; p=0.0062) and RSK1 312 
(1.03-fold ±0.01; p<0.018) and the down-regulation of GSK3-alpha (0.67-fold ±0.06; 313 
p=0.0419), JNK2 (0.54-fold ±0.04; p=0062) and p38 delta (0.66-fold ±0.01; p=0.0033). 314 
  315 
Effect of p38, ERK1/2 and JNK inhibitors on AQP4 protein expression in primary 316 
human cortical astrocytes using sandwich ELISA. 317 
Data are presented as fold-change compared to untreated astrocytes (n=4). Figure 6 shows 318 
that treating astrocytes with the p38 inhibitor caused a significant reduction in AQP4 protein 319 
expression (0.67-fold ± 0.01; p=0.014). A similar trend in reduction of AQP4 protein 320 
expression was seen after treating the cells with a JNK inhibitor (0.57-fold ± 0.009; p=0.007). 321 
There was no change in AQP4 protein expression in astrocytes following ERK1/2 inhibitor 322 
treatment (p value=0.27). 323 
 324 
Discussion 325 
This study has demonstrated a differential expression of AQPs 1, 4 and 9 transcripts, and 326 
revealed changes in AQP4 protein expression in human TLE-HS along with twelve key 327 
regulatory elements of the MAPK pathway by DAVID/KEGG analysis. Our results together 328 
with evidence of TLE-impaired water homeostasis (Bronen et al., 1991; Lee et al., 2004; 329 
Heuser et al., 2010; Dawe et al., 2014) may implicate these elements in the pathophysiology 330 
of TLE directly or indirectly through their effect on AQP expression.  331 
 332 
Regulation of water transport is increasingly being suggested as a mechanism in the 333 
aetiology of TLE (Bronen et al., 1991; Lee et al., 2004; Heuser et al., 2010; Dawe et al., 334 
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2014). A rapid increase in brain water-content can result in seizures (Andrew, 1991). 335 
Moreover, it has been suggested that seizures could cause cell swelling and a decrease in 336 
the size of the extracellular space (Janigro & Walker, 2014). This can result in an increase in 337 
the extracellular K+ concentration, which has a significant effect in increasing seizure 338 
susceptibility (Dietzel et al., 1980; Dudek & Rogawski, 2005). Experiments in AQP4 -/- mice 339 
suggested a direct role for AQP4 in controlling neurotransmission via modulating dopamine 340 
metabolism (Fan et al., 2005; Ding et al., 2007) and glutamate uptake (Li et al., 2012; Yan et 341 
al., 2013). Since elevated extracellular potassium and glutamate concentrations are well-342 
known drivers of epilepsy (Cho, 2013) and AQP4 appears to positively regulate the uptake of 343 
both of these molecules into astrocytes, it may be that the upregulation of AQP4 is a 344 
homeostatic response to high concentrations of these molecules. However, because AQP4 345 
is mislocalized in the astrocytes of the sclerotic hippocampus (Eid et al., 2005; Alvestad et 346 
al., 2013), this homeostatic response is insufficient for preventing seizures. 347 
In the present study, the whole-genome transcriptional profile was determined using 348 
microarray and the gene network analysing software DAVID and KEGG. Differentially 349 
expressed putative target genes, biomarkers and pathways that may play a role in TLE have 350 
been identified. This study reports that the transcript expression of AQPs 1 and 4 are 351 
significantly increased, while the transcript expression of AQP9 is significantly reduced in 352 
TLE-HS compared to TLE-NC. This was accompanied by a significant upregulation of the 353 
transcripts of the astrocytic biomarker, glial fibrillary acidic protein (GFAP) in TLE-HS 354 
compared to TLE-NC, which reflects a state of gliosis in TLE-HS (Lee et al., 2004). The 355 
transcripts of the neuronal biomarker, neuronal nuclear antigen (NeuN), was significantly 356 
decreased in TLE-HS compared to TLE-NC which could refer to neuronal loss in sclerotic 357 
tissue samples (supplementary material Figure 1). 358 
 359 
Of the investigated cerebral AQP genes, transcriptome analysis indicated only a significant 360 
differential expression of AQP1, AQP4 and AQP9 transcripts. The ELISA data in this study 361 
showed a significant increase in AQP4 protein expression in sclerotic tissue samples 362 
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compared to the non-sclerotic samples from the same set of patients that followed the same 363 
trend of upregulation as seen at the mRNA level. This result is in qualitative agreement with 364 
the findings of Das et al who reported a ~1.8-fold increase in AQP4 protein expression in six 365 
sclerotic samples compared to three non-matched post-mortem controls. Similarly, Lee et al 366 
reported a 1.6-fold increase in AQP4 transcript by microarray and a 2.6-fold increase by 367 
qPCR in sclerotic hippocampi from four mesial TLE patients (MTLE) compared to three non-368 
matched TLE patients. This is qualitatively consistent with our observation of a 3.4-fold 369 
increase in AQP4 transcript by microarray in seven sclerotic hippocampi from TLE patients 370 
compared to matched non-sclerotic tissue. A study by Eid et al reported a 3.6-fold increase 371 
in AQP4 protein in six MTLE patient hippocampi compared to six non-MTLE controls, but a 372 
simultaneous loss of perivascular AQP4 localization attributed to loss of dystrophin 373 
localization. Bebek et al claimed that there was no change in AQP4 protein expression in 374 
five MTLE patients compared to five non-MTLE using paraffin sections and 375 
immunofluorescence. However, the number of AQP4-positive cells per field was the reported 376 
measure for AQP4 expression, but there was no attempt to measure changes in intensity of 377 
AQP4 staining in those positive cells. In addition, the authors reported that AQP4 transcript 378 
was unchanged in 23 MTLE samples compared to seven post-mortem controls. However, 379 
their control samples spanned a 1 million-fold range (normalised expression from 10-7 to 10-380 
1; see Bebek et al., Figure 1B), compared to a 4-fold range in our data (Rn values from 5,000 381 
to 20,000 (Figure 1). This large difference in sample-to-sample variability might explain why 382 
the data from some studies (Eid et al., 2005; Lee et al., 2004) and our data showed a 383 
significant difference in AQP4 expression whereas (Bebek et al., 2013) did not. Changes in 384 
differential AQP4 expression could be implicated in the pathophysiology of sclerosis via 385 
water-mediated changes in neuronal activity through AQP4-mediated water efflux at the end-386 
feet (Amiry-Moghaddam & Ottersen, 2003). 387 
Our microarray data have revealed a significant upregulation of AQP1 at the mRNA level. 388 
This result is in agreement with the findings reported through the transcriptomic analysis 389 
work by (Jamali et al., 2006). Normally in the hippocampus, AQP1 is only observed in 390 
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astrocytes or cerebrovascular endothelial cells under stress conditions. However, in a 391 
chronic model of status epilepticus (SE), AQP1 expression was observed in astrocytes 392 
following SE at 4 weeks, and was up-regulated at 6 weeks when a significant up-regulation 393 
was reported in epileptic hippocampi compared to control (Kim et al., 2009). In addition, 394 
AQP1 expression in cerebrovascular endothelial cells is only highly expressed in conditions 395 
where the blood brain barrier (BBB) is disrupted such as in malignant brain tumours 396 
(Papadopoulos & Verkman, 2013). There is transient opening of the BBB during SE, which 397 
shows epileptogenic effects and also induces inflammation (Kovács et al., 2012; Gorter et 398 
al., 2015). Therefore, in drug resistant TLE hippocampi, AQP1 expression could be induced 399 
in endothelial cells, which could facilitate water movement across the BBB but this needs to 400 
be confirmed and validated using immunohistochemical studies. However, the AQP1 ELISA 401 
data reveal that there was no significant difference in AQP1 protein levels between TLE-HS 402 
and TLE-NC samples which could be due various translational regulation mechanisms.  403 
 404 
It is well known that regulatory mechanisms underlying AQP gene and protein expression 405 
are complex and could be influenced by various physiological, pathological or regulatory 406 
stimuli, including hormones (Gu et al., 2003), cytokines (Yang et al., 1995) and/or stress 407 
activated signals (Arima et al., 2003). For example, hypertonic stress upregulated AQP1 408 
expression in rodent renal medullary cells by inducing an extracellular signal-regulated 409 
kinase including p38 and JNK, which regulate a hypertonicity-responsive element present in 410 
the AQP1 promoter (Umenishi & Schrier, 2003). It has been shown that some pathological 411 
conditions including multiple sclerosis could result in simultaneous upregulation of AQP1 and 412 
AQP4 (Satoh et al., 2007). However this is not always the case, as suggested by the data 413 
from our study, which is supported by comparable findings (Mao et al., 2006) showing that 414 
inducing severe hydrocephalus stimulated AQP4, but not AQP1, protein expression in 415 
perivascular astrocytes. 416 
 417 
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Restoration of the ion gradients, after seizures, requires energy and an enhanced oxygen 418 
and glucose consumption; in fact, it was found that during epileptic activity there is a 419 
reduction in levels of glucose and ATP in the tissue as well as an increased level of lactate 420 
(Folbergrová et al., 2000). In order for the neurons to meet this enormous metabolic demand 421 
they use glycerol and lactate as a source of energy (Magistretti et al., 1999; Badaut et al., 422 
2014). The aquaglyceroporin, AQP9, is expressed in both astrocytes and neurons in the 423 
brain. AQP9 is able to transport both glycerol and lactate, therefore, it may play a vital role in 424 
the changes in astrocyte and neuronal energy metabolism that occurs in response to seizure 425 
activity (Amiry-Moghaddam & Ottersen, 2003; Badaut & Regli, 2004). In the present study, 426 
the total AQP9 transcript level is reduced in TLE-HS compared to TLE-NC indicating that it 427 
might be contributing to the pathophysiology of TLE-HS; however, these results need to be 428 
confirmed at the protein level in future studies. 429 
 430 
DAVID and KEGG analysis of the microarray data identified that 50 of the 3,333 differentially 431 
regulated genes were most commonly associated with the MAPK pathway in TLE-HS 432 
compared to TLE-NC, as indicated in Figure 4. Interestingly, it has been shown that the p38 433 
MAPK-dependent pathway is possibly the primary mechanism in controlling the altered 434 
expression of a number of major AQPs including AQP4 and AQP9 (Fujita et al., 2003) as 435 
well as AQPs 3, 5 and 8 (Yang et al., 2013b). This study has identified changes in AQP4 436 
protein expression in human TLE-HS and key regulatory elements of the MAPK pathway by 437 
DAVID/KEGG analysis. Our results (Figure 6) reveals that the activity of p38 and JNK 438 
MAPKs, but not ERK1/2, contributes to the differential expression of AQP4 protein and 439 
hence the astrocytic response to changes in water homeostasis. These results are in 440 
agreement with previous reports using cultured astrocytes and in animal models (Rama Rao 441 
et al., 2010; Rao et al., 2011). Our results together with evidence of TLE-impaired water 442 
homeostasis (Bronen et al., 1991; Lee et al., 2004; Heuser et al., 2010; Dawe et al., 2014) 443 
may implicate these elements in the pathophysiology of TLE directly or indirectly through 444 
their effect on AQP expression, therefore revealing possible new therapeutic targets. Further 445 
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studies investigating the effects of p38 and JNK inhibitors on animal models of epilepsy will 446 
be needed to validate these findings. 447 
 448 
The up-regulation of ERK2 at the genetic and protein levels could be linked to the 449 
mechanism underlying the pathophysiology of sclerotic TLE. ERK activation has been 450 
reported to induce epilepsy in mouse models by stimulating the N-methyl-D-aspartate 451 
(NMDA) receptor. The ERK signalling cascade may contribute to the aetiology underlying 452 
some other epileptic types in humans (Nateri et al., 2007). The present study also reveals a 453 
significant increase in p53 protein in the sclerotic hippocampi of TLE patients.  This is 454 
consistent with immunohistochemical data that showed up-regulation of p53 in the 455 
hippocampi of TLE patients (Xu et al., 2007) along with a correlation between seizure-456 
activated neuronal death in rat hippocampi and p53 responses (Sakhi et al., 1994; Araki et 457 
al., 2004). However, neuropathological studies reveal that seizure-mediated cellular death in 458 
TLE happens in a very limited manner (Bernasconi et al., 2002; Mathern et al., 2002; Liu et 459 
al., 2003; Engel et al., 2007). This might suggest a pro-apoptotic effect of p53; this study 460 
suggested induced activities for several anti-apoptotic and cytoprotective signalling 461 
cascades including AKT and RSK. AKT is the key modulator of the AKT-mTOR signalling 462 
pathway that is involved in neurogenesis, dendrite development and synapse formation. This 463 
result is consistent with the recently published study by Griffin and colleagues (Griffin et al., 464 
2016) . RSK modulates mTOR signalling and is involved in cell survival and proliferation in 465 
addition to its role in inhibiting the pro-apoptotic function of Death-associated protein kinase 466 
1 (DAPK1) and Bcl-2-associated death promoter (BAD). Furthermore, these cytoprotective 467 
and anti-apoptotic properties could also be mediated by inhibition of JNK2 since JNK2 is 468 
known to stabilise p53 activity by blocking its ubiquitination (Fuchs et al., 1998; Bode & 469 
Dong, 2007); and additionally the inhibition of p38 delta (Zarubin & Jiahuai, 2005). 470 
Differential changes in apoptosis-related signalling cascades are largely found in TLE tissue. 471 
In humans, these findings could indicate that seizure-mediated stress could result in 472 
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alterations in gene expression between adaptive responses that inhibit the neuronal loss and 473 
the cell death signalling pathways. 474 
 475 
Seizures are usually associated with a high energetic demand due to abnormal 476 
simultaneous firing of a large number of neurons. As the seizure progresses, the increased 477 
level of lactic acid decreases the tissue pH and causes metabolic-acidosis, which terminates 478 
the seizure (Yang et al., 2013a). During seizures, there is a remarkable increase in 479 
glycolysis due to inhibited aerobic metabolism; lactic acid is utilised as one of the major 480 
sources of energy (Williamson et al., 2005). Previous clinical studies suggest that 481 
carbohydrate metabolism and glycolysis could induce susceptibility to epileptic attacks and 482 
inhibiting glycolysis could have antiepileptic effects (Huttenlocher, 1976). The results from 483 
this study show significant differential expression of a number of essential elements involved 484 
in cerebral energy metabolism including the upregulation of the beta isoform of glycogen 485 
synthase kinase-3 (GSK3β), but not the alpha isoform. GSK3β is known to act as a negative 486 
regulator in the hormonal control of glucose homeostasis and an inactivating agent of 487 
glycogen synthase (Cho, 2011). The dual specificity mitogen-activated protein kinase kinase 488 
3 (MKK3) is also upregulated. MKK3 is activated by mitogenic and environmental stress and 489 
also by insulin and it is necessary for the expression of the glucose transporter (mainly 490 
through its effect on GLUT1 and GLUT4) (Fujishiro et al., 2001; Zarubin & Jiahuai, 2005). 491 
Further understanding of the specific role of energy metabolism and homeostasis in TLE 492 
could shed light on TLE pathophysiology, and may help in identifying novel therapeutic 493 
strategies. 494 
In conclusion, the mechanisms involved in TLE aetiology are complex and currently no 495 
single factor that could explain the underlying pathophysiology has been identified. 496 
Understanding the signalling networks is essential for discovery and validation of new 497 
potential therapeutic targets and we have identified a number in this study using a global 498 
transcriptomic approach. Despite the essential role of AQPs in the pathophysiology of many 499 
diseases, including cerebral oedema, diabetes insipidus, cancer, TLE and many more, there 500 
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are still no clinically-available drugs that target AQPs specifically (Verkman, et al., 2014). 501 
Therefore, understanding the molecular mechanisms involved in their regulation could 502 
provide new insights into the treatment of epilepsy and pharmaco-resistant TLE in particular. 503 
Targeting molecules of the MAPK signalling pathway involved in the regulation of AQP4 504 
expression could be one important area for future studies. 505 
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Tables: 926 
 927 
Table 1. Patient clinical data:  928 
 929 
 Sex 
Age at 
surgery 
(years) 
Epilepsy 
duration 
(years) 
Samples Side Current AEDs Previous AEDs 
 
01 
F 34 33.5 
TLE-HS 
TLE-NC 
R LMT,LEV 
PB, PHT, CBZ, 
VPA 
02 F 32 13 
TLE-HS  
TLE-NC 
R 
LMT, CBZ, 
GBP 
LEV 
03 M 48 47 
TLE-HS 
TLE-NC 
R PER,CBZ 
PHT, LEV,LMT, 
GBP,TPM,PGB, 
ZNS 
04 F 51 40 
TLE-HS 
TLE-NC 
L LCS, LEV CBZ, LMT, VPA 
05 F 54 53 
TLE-HS  
TLE-NC 
L LMT,PGB 
GBP,VPA,PHT, 
CBZ,PB,LEV, 
CNP,LCS 
06 M 41 29 
TLE-HS  
TLE-NC 
L CBZ , LMT LEV, ZNS, PGB 
07 F 22 13 
TLE-HS 
TLE-NC 
R 
LCS, LMT, 
TPM, PB 
VPA 
08 F 25 6 
TLE-HS  
TLE-NC 
L LEV, PB,LCS PHT, LMT, CBZ 
09 M 42 8 
TLE-HS  
TLE-NC 
L LCS 
PER, LEV, CBZ, 
PHT 
10 M 33 24 TLE-HS L None CBZ,VPA, LEV 
AEDs: Antiepileptic drugs. CBZ: Carbamazepine. CLB: Clobazam. CNP: Clonazepam. 
GBP: Gabapentin. LCS: Lacosamide. LEV: Levetiracetam. LMT: Lamotrigine. NA: not 
available. OXC: Oxcabazepine. PB: Phenobarbital. PER: Perampanel. PGB: Pregabalin. 
PHT: Phenytoin. TGB: Tiagabine. TLE: Temporal lobe epilepsy. TLE-HS: spiking TLE 
sclerotic hippocampus. TLE-NC: non-spiking TLE superior temporal gyrus. TPM: 
Topiramate. VGB: Vigabatrin. VPA: Valproate. ZNS: Zonisamide. 
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Table 2: Fold change (FC) expression of MAPK target genes and corresponding 932 
proteins.  933 
 934 
MAPK Targets 
MAPK Gene Fold-
Change  
(TLE-HS/TLE-NC) 
Phosphorylated MAPK 
Protein Fold-Change 
 (TLE-HS/TLE-NC) 
AKT Pan - 3.78* 
ERK1 1.34**** ns 
ERK 2 2.75**** 2.33* 
GSK3 alpha 0.67* - 
GSK-3 beta 1.81**** ns 
HSP27 2.01** ns 
JNK 2 0.54** ns 
MKK3 1.15**** 2.26* 
p38 delta 0.66** ns 
p53 ns 2.89* 
RSK 1 1.03** ns 
RSK 2 ns 1.75* 
 935 
Table 2: Fold change (FC) was obtained by dividing the mean of the expression level in 936 
TLE-HS by the mean of its corresponding TLE-NC expression level. The data represent a 937 
comparative analysis for selected MAPK genes (normalized to array signal) and proteins 938 
(normalized to array control) in TLE-NC and TLE-HS. The results are presented as mean ± 939 
Standard Error of the Mean (S.E.M) for (n=7) for both TLE-NC and TLE-HS in microarray 940 
analysis; and (n=3) for both of TLE-NC and TLE-HS in proteome profiler analysis, using 941 
patient matched samples. Kruskal-Wallis with Conover-Inman post hoc analysis was used to 942 
identify significant differences between samples (*P < 0.05, ** P < 0.01, ***P < 0.001 and 943 
****P < 0.0001, ns = not significant). MA: microarray analysis. TLE: Temporal lobe epilepsy. 944 
TLE-HS: spiking TLE sclerotic hippocampus. TLE-NC: non-spiking TLE superior temporal 945 
gyrus. ns= not significant, - = data not available. 946 
 947 
 948 
  949 
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Figure captions:  950 
Figure 1: The mRNA expression profile of cerebral AQPs in TLE-HS and TLE-NC 951 
specimens investigated using microarray analysis. 952 
Histograms represent a comparative analysis for the cerebral AQP mRNA expression profile 953 
in TLE-HS and TLE-NC. Kruskall-Wallis with Conover-Inman post hoc analysis tests were 954 
used to identify significant differences between samples (*P < 0.05, ** P < 0.01 and ***P < 955 
0.001). Data presented as Mean ± S.E.M. Number of samples: TLE-HS (n=7); TLE-NC 956 
(n=7). MA: microarray analysis. TLE: Temporal lobe epilepsy. TLE-HS: spiking TLE sclerotic 957 
hippocampus. TLE-NC: non-spiking TLE superior temporal gyrus. MA KCNJ10: potassium 958 
voltage-gated channel subfamily J member. 959 
 960 
Figure 2: The translational profile of (A) AQP4 and (B) AQP1 in TLE-NC and TLE-HS 961 
specimens investigated by sandwich ELISA.  962 
The AQP4 protein level was significantly up-regulated in TLE-HS. The protein level of AQP1 963 
was increased in TLE-HS, though was not statistically significant. Kruskall-Wallis with 964 
Conover-Inman post hoc analysis tests were used to identify significant differences between 965 
samples (**** P < 0.0001).  Number of samples:  TLE-NC (n = 3); TLE-HS (n = 3) paired 966 
samples. All data presented as Mean ± S.E.M. TLE: Temporal lobe epilepsy. TLE-HS: 967 
spiking TLE sclerotic hippocampus. TLE-NC: non-spiking TLE superior temporal gyrus. 968 
 969 
Figure 3: KEGG Pathway Enrichment Analysis for differentially-expressed genes in 970 
TLE-HS vs TLE-NC  971 
Data represent KEGG Pathway Enrichment Analysis for differentially-expressed genes 972 
(DEGs) in TLE-HS vs TLE-NC. The Enrichment Score value for each KEGG Pathway is 973 
reported on the side of each bar and the number of genes identified in each pathway is 974 
reported as a number inside each bar. 975 
 976 
Figure 4: The distribution of the differentially-expressed genes within the detected 977 
MAPK signalling pathway in TLE-HS (adapted from KEGG website: 978 
www.genome.jp/kegg) 979 
The significant up- and down-regulated MAPK related genes, indicated with red and yellow 980 
stars respectively, were identified using DAVID/KEGG enrichment analysis of microarray 981 
data. The pathway enrichment score was 6.1 and the total number of enriched genes was 50 982 
(27 genes were significantly down-regulated while 23 genes were significantly up-regulated). 983 
Number of samples: TLE-HS (n=7); TLE-NC (n=7). 984 
 985 
Figure 5: MAPK signalling profile in TLE-NC and TLE-HS samples (A) microarray 986 
analysis for mRNA expression and B) proteome profiling analysis.  987 
Histograms represent a comparative analysis for selected MAPK genes and proteins in TLE-988 
NC and TLE-HS. Kruskal-Wallis with Conover-Inman post hoc analysis tests were used to 989 
identify significant differences between samples (*P < 0.05, ** P < 0.01, ***P < 0.001 and 990 
****P < 0.0001). Data presented as Mean ± S.E.M. Number of samples: MA (n=7); proteome 991 
profiler analysis (n=3). MA: microarray analysis. Rn: Normalized fluorescence intensity. TLE: 992 
Temporal lobe epilepsy. TLE-HS: spiking TLE sclerotic hippocampus. TLE-NC: non-spiking 993 
TLE superior temporal gyrus. 994 
 995 
Figure 6. The correlation between p38, ERK1/2 or JNK inhibition and AQP4 protein 996 
expression in primary human astrocytes. Data are mean fold-changes in expression (± 997 
S.E.M) (n=4). The p38 inhibitor is 10 µM SB203580; the ERK1/2 inhibitor is 10 µM PD98059; 998 
and the JNK inhibitor is 40 µM SP600125. FC: fold-change. Each bar represents the 999 
normalized mean ± S.E.M for each of the conditions. * represents statistical significance (p < 1000 
0.05). 1001 
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Supplementary material: 1139 
 1140 
Supplementary Figure 1: 1141 
 1142 
 1143 
 1144 
 1145 
 1146 
Supplementary Figure 1: The mRNA expression profile of NeuN and GFAP in TLE-HS 1147 
and TLE-NC specimens investigated using microarray analysis. 1148 
Histograms represent a comparative analysis for NeuN and GFAP mRNA expression profile 1149 
in TLE-HS and TLE-NC. Kruskall-Wallis with Conover-Inman post hoc analysis tests were 1150 
used to identify significant differences between samples (*P < 0.05, ** P < 0.01 and ***P < 1151 
0.001). Data presented as Mean ± S.E.M. Number of samples: TLE-HS (n=7); TLE-NC 1152 
(n=7). MA: microarray analysis. TLE: Temporal lobe epilepsy. TLE-HS: spiking TLE sclerotic 1153 
hippocampus. TLE-NC: non-spiking TLE superior temporal gyrus. 1154 
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 1179 
Supplementary Table 1: 1180 
 1181 
Supplementary Table 1:  Functional annotation clustering of differentially expressed genes 1182 
(DEGs): Cluster1-3    1183 
Annotation Cluster 1 Enrichment Score: 6.72 
Category Term Count P Value 
SP_PIR_KEYWORDS signal 97 4.44E-09 
SP_PIR_KEYWORDS disulphide bond 90 4.90E-09 
UP_SEQ_FEATURE signal peptide 97 6.18E-09 
UP_SEQ_FEATURE disulphide bond 87 1.20E-08 
UP_SEQ_FEATURE glycosylation site: N-linked (GlcNAc...) 98 1.72E-04 
SP_PIR_KEYWORDS glycoprotein 101 1.76E-04 
Annotation Cluster 2 Enrichment Score: 5.96 
Category Term Count P Value 
SP_PIR_KEYWORDS signal 97 4.44E-09 
UP_SEQ_FEATURE signal peptide 97 6.18E-09 
SP_PIR_KEYWORDS Secreted 55 2.51E-06 
GOTERM_CC_FAT GO:0044421~extracellular region part 39 3.49E-06 
GOTERM_CC_FAT GO:0005576~extracellular region 64 4.44E-06 
GOTERM_MF_FAT GO:0005125~cytokine activity 15 1.02E-05 
SP_PIR_KEYWORDS cytokine 14 1.15E-05 
GOTERM_CC_FAT GO:0005615~extracellular space 30 1.67E-05 
Annotation Cluster 3 Enrichment Score: 5.51 
Category Term Count P Value 
GOTERM_BP_FAT GO:0006954~inflammatory response 22 8.58E-07 
GOTERM_BP_FAT GO:0006952~defense response 31 1.59E-06 
GOTERM_BP_FAT GO:0009611~response to wounding 26 2.18E-05 
BP: Biological Processes. CC: Cellular Components. GO: Gene ontology. GOTERM: Gene 
ontology term. INTERPRO: protein sequence analysis & classification resource. MF: 
Molecular Functions. PIR:  Protein Information Resource annotation. SMART: Simple 
Modular Architecture Research Tool. SP: SwissProt Protein Knowledgebase. 
UP_SEQ_FEATURE: Uniprot Sequence annotations.  
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